Analysts Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) PT at $10.00

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $10.00.

Several brokerages have issued reports on SABS. Guggenheim initiated coverage on SAB Biotherapeutics in a research report on Friday, December 19th. They issued a “buy” rating and a $15.00 target price on the stock. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of SAB Biotherapeutics in a report on Monday, December 29th. UBS Group began coverage on shares of SAB Biotherapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $7.00 target price for the company. Finally, Chardan Capital reiterated a “buy” rating and set a $12.00 price target on shares of SAB Biotherapeutics in a research note on Thursday, December 18th.

Hedge Funds Weigh In On SAB Biotherapeutics

Several large investors have recently added to or reduced their stakes in SABS. HB Wealth Management LLC bought a new position in shares of SAB Biotherapeutics in the third quarter worth approximately $618,000. Dimensional Fund Advisors LP bought a new position in SAB Biotherapeutics in the 3rd quarter worth $32,000. ADAR1 Capital Management LLC bought a new position in SAB Biotherapeutics in the 3rd quarter worth $30,000. Virtu Financial LLC purchased a new stake in SAB Biotherapeutics in the 3rd quarter worth $40,000. Finally, Commodore Capital LP bought a new stake in SAB Biotherapeutics during the third quarter valued at about $8,847,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Trading Up 1.0%

Shares of SABS stock opened at $4.04 on Friday. The company has a current ratio of 10.49, a quick ratio of 10.50 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a 12-month low of $1.00 and a 12-month high of $6.60. The stock has a market capitalization of $192.34 million, a P/E ratio of -1.31 and a beta of 0.58. The firm’s 50 day moving average is $3.85 and its 200 day moving average is $2.95.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.38. Research analysts expect that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.